Project Grant P20CA290458

This federal Project Grant award, provided by the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is funding research at the University of Texas Southwestern Medical Center (UT Southwestern) to define the role of the RCOR2 gene in hypoxia-induced immune evasion and its potential therapeutic applications for triple-negative breast cancer. The $1.64 million award, effective from June 1, 2024 through May 31, 2027, will support...

The University of Miami received a $254,333 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective September 23, 2025, with completion targeted by August 31, 2027. The award supports a comparative research initiative examining racial disparities in breast cancer risk and gene expression by recruiting 250 African Zambian women with pathologically confirmed breast cancer at the Cancer Disease Hospital in Lusaka, Zambia....

This federal Project Grant award of $589,591.00 from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) aims to determine how social factors may explain poorer survival outcomes for Black and Hispanic patients with Hodgkin lymphoma. The key products and services to be delivered under this 5-year project include: Examining differences in the receipt and quality of Hodgkin lymphoma treatment for initial diagnosis and relapse for those who have...

Federal Project Grant Summary The National Cancer Institute awarded a $649,293 Project Grant to Ochin, Inc. on September 23, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a longitudinal, multi-level study examining healthcare utilization and outcomes across the cancer care continuum with a focus on social risk factors affecting Latino patients. The research utilizes an electronic health record (EHR)-based dataset from a community health center network...

This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...

Federal Grant Award Summary The National Institute on Minority Health and Health Disparities (NIMHD) awarded the University of California, San Francisco (UCSF) a $8.6 million Project Grant (CFDA 93.307: Minority Health and Health Disparities Research) beginning September 1, 2025, and extending through June 30, 2029. This research initiative focuses on identifying germline variation in homologous recombination repair (HRR) genes and their association with breast cancer risk and treatment response...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $807,644 Project Grant on August 13, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and pilot DESCANSO, a culturally adapted cognitive behavioral therapy (CBT) intervention for Spanish-speaking Latino cancer patients. The intervention addresses a symptom cluster of depression, insomnia, and fatigue (DIF) that disproportionately affects Latino cancer patients compared to...

This federal Project Grant award of $378,444, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), will support research by Trustees of Indiana University, Indianapolis to investigate the role of Heat Shock Factor 1 (HSF1) in regulating immune cell infiltration into metastatic breast tumors. The goal is to determine how HSF1 activity impacts the recruitment of CD8+ T cells and other anti-tumor immune cells to metastatic breast cancer, with the...

The National Cancer Institute (NCI), under the federal Cancer Biology Research grant program (CFDA 93.396), awarded a $218,089 Project Grant to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel chimeric antigen receptor macrophage (CAR-M) immunotherapy for the treatment of triple-negative breast cancer (TNBC). The project, titled "RAC-Enhanced Chimeric Antigen Receptor-Macrophage (RACE-CAR-M) Immunotherapy for Triple Negative Breast Cancer," aims to...

Yale University received a $482,312 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 2, 2026, through March 31, 2031. The award funds research to develop a novel therapeutic approach for inactivating regulatory T (Treg) cells through targeted protein degradation as a strategy to overcome immunotherapy resistance in cancer patients. The research builds on preliminary findings demonstrating that degradation of...